Objective: In this study, we aimed to evaluate the effect of rasagiline treatment on motor and non-motor symptoms in patients with Parkinson’s disease (PD).
Background: Prospective studies showed that the rasagiline may be effective on many of motor and non-motor symptoms such as fatigue and postural instability and also reduce the wearing-off frequency in early and advanced stages of PD.
Method: 428 PD patients (259 males, 60.5%) were evaluated retrospectively. Demographic data, modified Hoehn&Yahr (mH&Y) stages, Unified Parkinson’s Disease Rating Scale (UPDRS) part II, III and Mini Mental State Examination (MMSE) scores and L-dopa equivalent doses were recorded. The tremor, rigidity, bradykinesia, gait/postural instability sub-scores of UPDRS part III, which determines the motor features of the disease, were calculated and the presence of motor fluctuations and dyskinesias were recorded. Non-motor symptoms were determined through a semi-structured non-motor symptoms questionnaire. Patient groups of with-rasagiline treatment (using rasagiline 1mg/day for at least 3 weeks) and without-rasagiline treatment were compared in terms of motor and non-motor symptoms of the disease.
Results: The mean age of the patients was 64.5 ± 10.1 years, and the mean disease duration was 6.8 ± 6.0 years. Although the disease duration of with-rasagiline treatment group was shorter (p <0.003), than without-rasagiline treatment group there was no difference between the groups in terms of mH&Y stages and UPDRS part II scores. Patients of with-rasagiline treatment group had statistically significantly lower UPDRS part III and gait/postural instability scores than without-rasagiline treatment group (p <0.02 and p <0.007, respectively). In addition, with-rasagiline treatment group patients had higher MMSE scores and less frequent restless legs syndrome (p <0.04 and p <0.004, respectively).
Conclusion: Despite the disease duration of with-rasagiline treatment group is shorter than without-rasagiline treatment group, results of our single-center, retrospective study indicates that rasagiline may have a favorable effect on motor and non-motor symptoms of PD such as gait/postural instability, cognitive impairment, and restless legs syndrome.
To cite this abstract in AMA style:
B.G Koçer, E.A Özturk, SS. Çomoğlu. The Effect of Rasagiline on Motor and Non-Motor Symptoms in Parkinson’s Disease [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/the-effect-of-rasagiline-on-motor-and-non-motor-symptoms-in-parkinsons-disease/. Accessed June 14, 2025.« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-effect-of-rasagiline-on-motor-and-non-motor-symptoms-in-parkinsons-disease/